ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.875
0.01%
Brent Oil
82.765
0.00%
Bitcoin
63,827.58
-0.10%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Johnson and Johnson (JNJ)

  7. Johnson and Johnson (JNJ) News

Johnson and Johnson (JNJ)

Johnson and Johnson
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:JNJ
DateTimeSourceHeadlineSymbolCompany
01/05/202411:30Business WireJohnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” ReorganizationNYSE:JNJJohnson and Johnson
22/04/202421:30Business WireJohnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)NYSE:JNJJohnson and Johnson
19/04/202412:31IH Market NewsParamount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and MoreNYSE:JNJJohnson and Johnson
17/04/202411:59IH Market NewsUS Index Futures See Gains, Oil Prices DipNYSE:JNJJohnson and Johnson
16/04/202421:33IH Market NewsU.S. Stocks Finish Lackluster Session Narrowly MixedNYSE:JNJJohnson and Johnson
16/04/202415:46Business WireCORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 ResultsNYSE:JNJJohnson and Johnson
16/04/202414:52IH Market NewsJ&J’s Q1 2024 sales rise 2.3% to $21.4 billionNYSE:JNJJohnson and Johnson
16/04/202414:09IH Market NewsDow Looks To Snap Six-Day Losing Streak As UnitedHealth SurgesNYSE:JNJJohnson and Johnson
16/04/202412:19IH Market NewsU.S. Index Futures Signal Mixed Trading, Oil Prices DipNYSE:JNJJohnson and Johnson
16/04/202412:18IH Market NewsEricsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More NewsNYSE:JNJJohnson and Johnson
16/04/202411:25Business WireJohnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%NYSE:JNJJohnson and Johnson
16/04/202411:20Business WireJohnson & Johnson Reports Q1 2024 ResultsNYSE:JNJJohnson and Johnson
15/04/202421:38IH Market NewsU.S. Stocks Extend Sell-Off As Treasury Yields Surge After Retail Sales DataNYSE:JNJJohnson and Johnson
08/04/202423:06Business WireJohnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceNYSE:JNJJohnson and Johnson
06/04/202404:21PR Newswire (US)CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of TherapyNYSE:JNJJohnson and Johnson
05/04/202419:55PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.NYSE:JNJJohnson and Johnson
05/04/202412:38IH Market NewsApple Terminates 614 Employees, Disney Unveils June Crackdown on Password Sharing, and More UpdatesNYSE:JNJJohnson and Johnson
05/04/202411:31Business WireJohnson & Johnson to Acquire Shockwave MedicalNYSE:JNJJohnson and Johnson
04/04/202423:01Business WireJohnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment CorporationNYSE:JNJJohnson and Johnson
02/04/202421:30Business WireJohnson & Johnson to Participate in the BofA Securities Health Care ConferenceNYSE:JNJJohnson and Johnson
28/03/202413:48IH Market NewsWalgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest NewsNYSE:JNJJohnson and Johnson
27/03/202410:54IH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNYSE:JNJJohnson and Johnson
12/03/202413:15GlobeNewswire Inc.Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation ChallengeNYSE:JNJJohnson and Johnson
11/03/202420:30Business WireJohnson & Johnson to Host Investor Conference Call on First-Quarter ResultsNYSE:JNJJohnson and Johnson
07/03/202421:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
07/03/202421:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
07/03/202413:33Business WireJohnson & Johnson Completes Acquisition of AmbrxNYSE:JNJJohnson and Johnson
06/03/202420:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
01/03/202420:59PR Newswire (US)RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNYSE:JNJJohnson and Johnson
20/02/202422:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
 Showing the most relevant articles for your search:NYSE:JNJ

Your Recent History

LSE
CHLL
Chill Brands
LSE
AGL
Angle
LSE
SRSP
Sirius Petroleum
LSE
SCE
Surface Transforms
LSE
AAZ
Anglo Asian Mining
LSE
POS
Plexus
LSE
SCLP
Scancell
LSE
AAU
Ariana Resources
LSE
SBTX
Skinbiotherapeutics
LSE
INSG
Insig Ai
LSE
LLOY
Lloyds Banking
LSE
HUM
Hummingbird Resources
LSE
BIRD
Blackbird
LSE
ALBA
Alba Mineral Resources
LSE
APTA
Aptamer
LSE
TERN
Tern
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved